News

September 13, 2019

Nanotechnology May Help Get Immunotherapy Into the Brain, Mouse Study Says

News

Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune ... Read more

September 11, 2019

FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan ... Read more

September 10, 2019

Health Canada and European Commission OK Tecentriq-Chemo Combo for Aggressive Lung Cancer

News

Health Canada and the European Commission have approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin plus etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), ... Read more

September 4, 2019

Trial of Targeted Radiation Therapy, CLR 131, in Children with Advanced Cancers Moving to Higher Dose

News

Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced ... Read more

September 3, 2019

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

News

A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high ... Read more

August 30, 2019

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

News

Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the ... Read more

August 28, 2019

$102.2M Pelotonia Gift to Help Establish Immuno-Oncology Institute at OSU

News

A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five ... Read more

August 27, 2019

EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma

News

A European Medicines Agency (EMA) committee has recommended orphan drug designation for Ziopharm Oncology‘s interleukin (IL)-12 gene therapy — known as the Controlled IL-12 platform — for the treatment of glioblastoma, ... Read more

August 27, 2019September 6, 2019

Study Explains Checkpoint Inhibitors’ Efficacy in PD-L1 Negative Tumors

News

Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are ... Read more

August 23, 2019

NKTR-214 with Opdivo Earns FDA’s Breakthrough Therapy Designation for Advanced Melanoma

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy NKTR-214 with Opdivo (nivolumab) for untreated melanoma patients with either metastatic disease or ... Read more

Pin It on Pinterest